TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11137591
Drug: Inadequate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inadequate treatment
Study: 11137591
Drug: Variability in
Normalized name: Ferric carbonate, ferric hydroxide, ferrous hydroxide (variable mixture)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Variability in antibiotic prescription
Study: 9205758
Drug: Ebrotidine single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebrotidine single doses (25 to 1600 mg)
Study: 9205758
Drug: Ebrotidine multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebrotidine multiple doses (400 to 800 mg every 12 hours for 12 days)
Study: 9205758
Drug: Ebrotidine (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebrotidine (single and multiple doses)
Study: 3076709
Drug: Mefloquine-sulfadoxine-pyrimethamine (MSP)
Normalized name: pyrimethamine / sulfadoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine-sulfadoxine-pyrimethamine (MSP) at doses of 1, 1.5, or 2 standard MSP tablets (equivalent to 7.1-12.5 mg/kg mefloquine, 14.3-25.0 mg/kg sulfadoxine, 0.7-1.3 mg/kg pyrimethamine)
Study: 25794622
Drug: TSHH (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: TSHH (7.5 μg tiotropium/25 μg salmeterol, once daily)
Study: 25794622
Drug: TioHH (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: TioHH (18 μg tiotropium, once daily)
Study: 25794622
Drug: SalD (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: SalD (50 μg salmeterol, twice daily)
Study: 25794622
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of TioHH (qd) plus SalD (bid)
Study: 23945570
Drug: Intramuscular gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular gentamicin once daily and oral amoxicillin twice daily for 7 days
Study: 23945570
Drug: Intramuscular penicillin
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular penicillin and gentamicin once daily for 2 days followed by oral amoxicillin twice daily for additional 5 days
Study: 23945570
Drug: Intramuscular procaine-benzyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular procaine-benzyl penicillin and gentamicin given once daily for 7 days
Study: 14504951
Drug: Subcutaneous adipose
Normalized name: human adipose preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous adipose tissue layers (SAT-layers) measured by LIPOMETER at various body sites.
Study: 9095609
Drug: PGE1 infusion
Normalized name: PGE1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PGE1 infusion at 0.02 microgram.kg‐1.min‐1 before induction of anesthesia
Study: 8240151
Drug: Simvastatin 10
Normalized name: simvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 10 mg daily, titrated to 40 mg daily
Study: 8240151
Drug: Pravastatin 10
Normalized name: pravastatin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 10 mg daily, titrated to 40 mg daily
Study: 24729041
Drug: Everolimus (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (4.5 mg/m²/day)
Study: 22951490
Drug: Rilpivirine (RPV)
Normalized name: Rilpivirine
DrugBank: Rilpivirine (DB08864)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rilpivirine (RPV) 25 mg once daily
Study: 21049089
Drug: Haloperidol 2-20
Normalized name: haloperidol 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 2-20 mg/day
Study: 21049089
Drug: Risperidone 2-10
Normalized name: risperidone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 2-10 mg/day
Study: 21049089
Drug: Ziprasidone 80-160
Normalized name: ziprasidone 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone 80-160 mg/day
Study: 18284439
Drug: Maintenance treatment
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance treatment with venlafaxine for 2 years
Study: 18284439
Drug: Maintenance treatment
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance treatment with venlafaxine
Study: 1806734
Drug: 650 mg
Normalized name: bran 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 650 mg of ASA
Study: 6859372
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of seminal plasma antibodies (titers up to 16)
Study: 6859372
Drug: Perioperative steroids
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative steroids (randomized controlled trial)
Study: 27189190
Drug: Podiatry treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Podiatry treatment
Study: 11576153
Drug: Caffeine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (6 mg kg(‐1))
Study: 16311460
Drug: New apparatus
Approvals — FDA: no, EMA: no, PMDA: no
Description: New apparatus for performing infusion tests in a standardized and automated way
Study: 2612300
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg ALEC powder
Study: 2612300
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml of 100 mg ALEC suspension
Study: 2612300
Drug: ALEC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALEC treatment
Study: 26244854
Drug: Telephone-delivered Cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-delivered Cognitive Behavioral Therapy (CBT)
Study: 23555980
Drug: Antimalarials only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimalarials only (intervention arm)
Study: 23555980
Drug: Antimalarials only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimalarials only (control arm)
Study: 16400044
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (500 mg Ca/d as calcium carbonate)
Study: 11406341
Drug: Basal intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal intravenous infusion of saline solution with verbal instructions of a powerful painkiller (double-blind administration)
Study: 8095149
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg noberastine
Study: 8095149
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg noberastine
Study: 18518727
Drug: Lumboventricular lavage
Normalized name: lovage oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumboventricular lavage and simultaneous low-frequency head-motion therapy
Study: 12784319
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg albendazole daily for 15 days
Study: 26481918
Drug: Oral propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral propranolol at a dose of 2 mg/kg per day in three divided doses
Study: 26481918
Drug: Oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibuprofen at a dose of 10 mg/kg 8-hourly and paracetamol at a dose of 16.2 mg/kg 8-hourly
Study: 22687786
Drug: rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 10 mg/day
Study: 22507978
Drug: pravastatin 20
Normalized name: pravastatin 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: pravastatin 20 mg/day
Study: 19835669
Drug: Escitalopram treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram treatment for 12 weeks
Study: 19835669
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (drug-free depressed patients)
Study: 10366081
Drug: Citicoline (Neuroton,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citicoline (Neuroton, 1000 mg/day intramuscularly for 60 days)
Study: 10366081
Drug: Placebo (physiologic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (physiologic solution with additives for 60 days)
Study: 10366081
Drug: Citicoline (second
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citicoline (second 60-day treatment) in GC2 patients
Study: 21173411
Drug: Blinded placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinded placebo pills (indistinguishable from echinacea)
Study: 15030841
Drug: Standard injection
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard injection method using Healon5
Study: 11211574
Drug: Chyawanprash (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chyawanprash (15 g/d)
Study: 29742699
Drug: Sham photobiomodulation
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham photobiomodulation in the sublingual region
Study: 28421782
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no analgesic maneuver)
Study: 24330893
Drug: Withania somnifera
Normalized name: WITHANIA SOMNIFERA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withania somnifera extract (WSE) 500 mg/d
Study: 7589376
Drug: Nebulized L-ASA
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized L-ASA (90 mg.ml-1)
Study: 7589376
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo (glycine solution, 30 mg.ml-1)
Study: 26920359
Drug: Neither marker
Normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neither marker of CKD (eGFR ≥60 mL/min/1.73 m(2) and UACR <30 mg/g)
Study: 24159258
Drug: Tiotropium 18
Normalized name: TIOTROPIUM 18MCG CAP,INHL,6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18 μg once daily
Study: 9671427
Drug: Betaxolol hydrochloride
Normalized name: Betaxolol Hydrochloride
DrugBank: Betaxolol (DB00195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betaxolol hydrochloride 0.25% (Betoptic S) administered to 17 POAG and 9 NTG eyes
Study: 8024354
Drug: Nutropin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutropin (0.2 mg/kg/day)
Study: 8024354
Drug: Protropin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protropin (0.2 mg/kg/day)
Study: 2925041
Drug: Intravenous phenylalanine
Normalized name: Phenylalanine
DrugBank: Phenylalanine (DB00120)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous phenylalanine before treatment with carbidopa
Study: 2925041
Drug: Carbidopa treatment
Normalized name: Carbidopa
DrugBank: Carbidopa (DB00190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbidopa treatment
Study: 11752106
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg subcutaneous methylnaltrexone plus morphine
Study: 11752106
Drug: Morphine (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.05 mg/kg intravenously)
Study: 8033514
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid infusion (240 kJ/h)
Study: 2558404
Drug: Non-fractioned heparin
Normalized name: OMIDUBICEL NON-CULTURED FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-fractioned heparin (NFH)
Study: 4142795
Drug: Bleomycin 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bleomycin 150 mg followed by radiation
Study: 28302407
Drug: AS03-adjuvanted H7N1
Normalized name: AS03 Adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03-adjuvanted H7N1 vaccine (3.75μg or 7.5μg hemagglutinin with AS03A or AS03B)
Study: 28302407
Drug: AS03-adjuvanted H7N1
Normalized name: AS03 Adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03-adjuvanted H7N1 vaccine
Study: 21562746
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg ZnSO(4) daily
Study: 17084137
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) delivered by general practitioners (GPs)
Study: 11335734
Drug: One 10-microg
Normalized name: sodium hyaluronate 10 MG/ML [Gel-One]
Approvals — FDA: no, EMA: no, PMDA: no
Description: One 10-microg dose
Study: 11335734
Drug: One 5-microg
Normalized name: 5-chlorobenzoxazolin-2-one
DrugBank: Chlorzoxazone (DB00356)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One 5-microg dose
Study: 11335734
Drug: Two or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two or three 5-microg doses
Study: 11335734
Drug: 2-dose regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose regimen of Recombivax HB
Study: 11335734
Drug: Two 10-microg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 10-microg doses
Study: 8392285
Drug: AZQ at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZQ at 15 mg/day for 3 days i.v. every 4 weeks
Study: 22664783
Drug: Rivaroxaban 15
Normalized name: rivaroxaban 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 15 mg once-daily
Study: 22664783
Drug: Warfarin (dose-adjusted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (dose-adjusted according to Japanese guidelines)
Study: 20832925
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg caffeine
Study: 11118463
Drug: Doxorubicin (DOX)
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin (DOX) 75 mg/m² and Cisplatin (CDDP) 100 mg/m² for six cycles at 3-week intervals; 232 (81%) received all six cycles.
Study: 9104519
Drug: Transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal fentanyl plus im ketorolac (Group A)
Study: 2822879
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg atenolol daily
Study: 23184118
Drug: Gastrografin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastrografin (3 mL/kg diluted 1:3 with water)
Study: 16821209
Drug: DHEA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA therapy (150 mg oral DHEA daily for 40 days)
Study: 14581438
Drug: Pamidronate disodium
Normalized name: Pamidronate Disodium
DrugBank: Pamidronic acid (DB00282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pamidronate disodium (90 mg) administered intravenously every 3 weeks for 27 weeks
Study: 8728804
Drug: Psychological preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological preparation (psychoprophylaxis)
Study: 3137888
Drug: Tegafur 400
Normalized name: tegafur
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Tegafur 400 mg/m2 and Tamoxifen 20 mg/daily (Group B)
Study: 28716108
Drug: Physiotherapy, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapy, 50 minutes per session, 4 weekly treatments
Study: 25703777
Drug: TVPS‐3 Visual
Approvals — FDA: no, EMA: no, PMDA: no
Description: TVPS‐3 Visual Sequential Memory, TVPS‐3 Visual Closure, and JTTHF dominant upper limb score
Study: 4073304
Drug: Structured treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured treatment (drug use exceeding set limits resulted in methadone withdrawal)
Study: 4073304
Drug: Unstructured treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unstructured treatment (no consequences attended continued drug use)
Study: 17516971
Drug: 1000 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 micrograms self-administered vaginal misoprostol
Study: 18485172
Drug: Self-administered vaginal
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered vaginal placebo
Study: 15612099
Drug: Sustained-release methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release methylphenidate tablets (18 mg to 54 mg/day in a single dose)
Study: 15612099
Drug: Sustained-release methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release methylphenidate capsules
Study: 15612099
Drug: Sustained-release methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release methylphenidate tablets
Study: 10871573
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin A (60 mg retinol equivalent)
Study: 1327742
Drug: 55 g
Normalized name: NexoBrid 8.8 % Topical Gel, 55 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 55 g high-fibre oat bran
Study: 1327742
Drug: 80 g
Normalized name: PEG-80 GLYCERYL COCOATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 g mixed cooked beans
Study: 21813065
Drug: sCD163 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sCD163 at baseline (1.69mg/l (1.42‐2.10))
Study: 12777644
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with ondansetron treatment
Study: 12777644
Drug: Ondansetron treatment
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron treatment alone
Study: 20562595
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg intravenous sotalol infusion administered over 2.5 hours
Study: 2589359
Drug: Clindamycin-gentamicin combination
Normalized name: clindamycin, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin-gentamicin combination
Study: 2589359
Drug: Intravenous followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous followed by oral ciprofloxacin
Study: 1099945
Drug: Ru-Tuss tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ru-Tuss tablets
Study: 21161185
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of hydrocortisone
Study: 21535999
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of hydrocortisone after learning
Study: 9624373
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (BTA) injection (4 units total: 2 units in each nasal cavity for middle and inferior turbinate)
Study: 3414581
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Zn/d
Study: 3414581
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (including vitamin-mineral supplement)
Study: 26940805
Drug: ABT-126 25
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-126 25 mg
Study: 28922590
Drug: ABT-126 75
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-126 75 mg
Study: 19556043
Drug: Urine total
Normalized name: Urin DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urine total protein level of 3.5 g/d or greater at baseline
Study: 12397539
Drug: R-FCM (Rituximab
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-FCM (Rituximab + Fludarabine-Cyclophosphamide-Mitoxantrone); Rituximab 375 mg/m2 one day before FCM
Study: 10211309
Drug: Retinyl palmitate
Normalized name: Retinyl palmitate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retinyl palmitate (300,000 I.U. daily for 1 month)
Study: 2196145
Drug: Pentoxifylline 800
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline 800 mg
Study: 6129874
Drug: Clemastine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clemastine (2 mg/day)
Study: 17551300
Drug: Intravenous vinorelbine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vinorelbine 30 mg/m2 weekly
Study: 17551300
Drug: Oral vinorelbine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vinorelbine for patients with KPS 60-70
Study: 7594341
Drug: Lansoprazole (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (group L)
Study: 2343792
Drug: Audiotaped administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Audiotaped administration of the Situational Competency Test (SCT)
Study: 31337325
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as Usual (Referral to PTSD 'Standard Care')
Study: 24007599
Drug: Physical activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical activity prescription + hyper‐corrective night‐time brace
Study: 24007599
Drug: Physical activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical activity prescription + postural scoliosis‐specific exercises
Study: 24007599
Drug: Physical activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical activity prescription (control group)
Study: 21285388
Drug: Premixed insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Premixed insulin aspart 70/30 BID (PIA)
Study: 19002124
Drug: Late delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late delivery of stem cells via intramyocardial injection and intracoronary infusion (3-4 months after AMI)
Study: 10212779
Drug: Ciprofloxacin (CPFX)
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin (CPFX) 200 mg in a single oral dose (group A)
Study: 10212779
Drug: Ciprofloxacin (CPFX)
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin (CPFX) 200 mg once daily for 3 days (group B)
Study: 10212779
Drug: Ciprofloxacin (CPFX)
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin (CPFX) 200 mg twice daily for 3 days (group C)
Study: 10212779
Drug: Cefpodoxime-proxcetil (CPDX-PR)
Normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefpodoxime-proxcetil (CPDX-PR) 200 mg once daily for 3 days (group D)
Study: 7786823
Drug: Early alternating
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early alternating chemotherapy (ABABAB)
Study: 7786823
Drug: Both early
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both early and late alternating chemotherapy
Study: 7786823
Drug: Late alternating
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late alternating chemotherapy (AAABBB)
Study: 468745
Drug: Digit temperature
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digit temperature biofeedback plus Rational-Emotive Therapy (RET)
Study: 23033886
Drug: Selenium-enriched yeast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium-enriched yeast (100 μg daily for 3 months)